Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer's Disease in Amnestic Mild Cognitive Impairment.

Park JE, Choi KY, Kim BC, Choi SM, Song MK, Lee JJ, Kim J, Song HC, Kim HW, Ha JM, Seo EH, Song WK, Park SG, Lee JS, Lee KH.

Dement Geriatr Cogn Dis Extra. 2019 Mar 12;9(1):100-113. doi: 10.1159/000496920. eCollection 2019 Jan-Apr.

2.

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study.

Lauridsen C, Sando SB, Shabnam A, Møller I, Berge G, Grøntvedt GR, Bakken IJ, Salvesen Ø, Bråthen G, White LR.

Front Aging Neurosci. 2016 Mar 1;8:30. doi: 10.3389/fnagi.2016.00030. eCollection 2016.

3.

Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A.

J Alzheimers Dis. 2015;45(4):1077-88. doi: 10.3233/JAD-142952.

PMID:
25649653
4.

Clinical indications for analysis of Alzheimer's disease CSF biomarkers.

Engelborghs S.

Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6. Review.

PMID:
24016466
5.

Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.

Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.

Bipolar Disord. 2016 Feb;18(1):63-70. doi: 10.1111/bdi.12360. Epub 2016 Feb 15.

PMID:
26876913
6.

A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.

Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, De Roeck E, De Vil B, Cras P, Martin JJ, De Deyn PP, Bjerke M, Engelborghs S.

J Alzheimers Dis. 2016 Aug 10;54(1):383-95. doi: 10.3233/JAD-151097.

PMID:
27567807
7.

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia.

Forlenza OV, Radanovic M, Talib LL, Aprahamian I, Diniz BS, Zetterberg H, Gattaz WF.

Alzheimers Dement (Amst). 2015 Oct 3;1(4):455-63. doi: 10.1016/j.dadm.2015.09.003. eCollection 2015 Dec.

8.

Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.

Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.

J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731.

PMID:
26923009
9.

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.

Caminiti SP, Ballarini T, Sala A, Cerami C, Presotto L, Santangelo R, Fallanca F, Vanoli EG, Gianolli L, Iannaccone S, Magnani G, Perani D; BIOMARKAPD Project.

Neuroimage Clin. 2018 Jan 28;18:167-177. doi: 10.1016/j.nicl.2018.01.019. eCollection 2018.

10.

Analysis of combined CSF biomarkers in AD diagnosis.

De Riva V, Galloni E, Marcon M, Di Dionisio L, Deluca C, Meligrana L, Bolner A, Perini F.

Clin Lab. 2014;60(4):629-34.

PMID:
24779297
11.

Biomarker positive and negative subjects in the ADNI cohort: clinical characterization.

Kennedy RE, Schneider LS, Cutter GR; Alzheimer's Disease Neuroimaging Initiative.

Curr Alzheimer Res. 2012 Dec;9(10):1135-41.

PMID:
22963265
12.

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, Teunissen CE, Parnetti L.

Alzheimers Dement. 2014 Nov;10(6):808-17. doi: 10.1016/j.jalz.2014.03.003. Epub 2014 Aug 20.

PMID:
25150736
13.

CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.

Spallazzi M, Barocco F, Michelini G, Immovilli P, Taga A, Morelli N, Ruffini L, Caffarra P.

Acta Neurol Belg. 2019 Mar 7. doi: 10.1007/s13760-019-01112-8. [Epub ahead of print]

PMID:
30847669
14.

AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis.

Stefani A, Bernardini S, Panella M, Pierantozzi M, Nuccetelli M, Koch G, Urbani A, Giordano A, Martorana A, Orlacchio A, Federici G, Bernardi G.

J Neurol Sci. 2005 Oct 15;237(1-2):83-8.

PMID:
15990115
15.

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.

Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM.

Arch Neurol. 2011 Sep;68(9):1137-44. doi: 10.1001/archneurol.2011.105. Epub 2011 May 9.

16.

Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis.

Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin JJ, De Deyn PP, Engelborghs S.

Front Neurol. 2015 Jun 17;6:138. doi: 10.3389/fneur.2015.00138. eCollection 2015.

17.

Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.

Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.

J Alzheimers Dis. 2016 Jul 29;54(1):157-68. doi: 10.3233/JAD-160176.

PMID:
27472875
18.

Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.

Chiasserini D, Biscetti L, Farotti L, Eusebi P, Salvadori N, Lisetti V, Baschieri F, Chipi E, Frattini G, Stoops E, Vanderstichele H, Calabresi P, Parnetti L.

J Alzheimers Dis. 2016 Jul 22;54(1):55-67. doi: 10.3233/JAD-160298.

PMID:
27447425
19.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
20.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group.

J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.

PMID:
26401938

Supplemental Content

Support Center